|
Alfresa Holdings Corporation is a holding company that manages a group of subsidiaries engaged in the pharmaceutical and healthcare sectors. The group's primary business segments include the wholesale distribution of medical pharmaceuticals, diagnostic reagents, and medical devices, led by Alfresa Co., Ltd. and regional subsidiaries such as Shikoku Alfresa, TS Alfresa, Meisho, Ryu-Yaku, and Tohoku Alfresa. The Self-Medication wholesale segment, operated by Alfresa Healthcare, distributes general pharmaceuticals, health foods, and related products. In the manufacturing segment, Alfresa Pharma produces pharmaceuticals, diagnostic reagents, medical devices, and APIs, supported by subsidiaries including Qingdao Naisike Medical Devices Co., Ltd. and Alfresa Fine Chemical. The group also operates a chain of community pharmacies through Apocrite. Additional business activities include SPD (Supply Processing and Distribution) services for hospital logistics, CRO and PMS services via ArkMS, and the development of regenerative medicine products and cell materials by Cell Resources. The company also provides IT system operations and maintenance through Alfresa System and engages in insurance agency and real estate management via Alfresa Biz Support. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Medical Distribution | Homepage alfresa.com |
| Sector Healthcare | IR page alfresa.com | |
|
Tags
pharmaceutical wholesale, medical devices, diagnostic reagents, pharmacy operations, pharmaceutical manufacturing, apis, spd services, cro, pms, regenerative medicine, health foods, Alfresa Co. Ltd., Shikoku Alfresa, TS Alfresa, Meisho, Ryu-Yaku, Tohoku Alfresa, Alfresa Medical Service, Alfresa Shinohara Chemical, S.M.D., A.L. Plus, Miyazaki Onsendo Shoten, Techno Suzuta, Alfresa Healthcare, Alfresa Pharma, Qingdao Naisike Medical Devices Co. Ltd., Alfresa Fine Chemical, Apocrite, Alfresa System, Cell Resources, ArkMS, Alfresa Biz Support
|
Press page alfresa.com/ir/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 436.355B |
| Market cap (USD) | $ 2.727B |
| P/E | 10.72 |
| PEG | 0.62 |
| P/BV | 0.88 |
| P/S | 0.14 |
| P/OCF | 9.80 |
| P/FCF | 20.04 |
| Dividend yield | 3.0% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 8.4% |
| ROI | 8.1% |
| ROIC | 4.7% |
| Profit margin | 1.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | 17.4% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 22.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.104T | 2.961T | 2.859T | 2.696T | 2.586T | 2.603T | 2.699T | 2.641T | 2.603T | 2.552T | 2.576T | 2.421T | 2.505T | 2.388T |
| Net profit | 41.746B | 27.389B | 29.558B | 25.786B | 32.182B | 24.501B | 40.273B | 41.699B | 35.589B | 30.893B | 34.975B | 22.922B | 25.566B | 20.771B |
| Free cash flow | 10.041B | -14.489B | 71.051B | -12.379B | 19.558B | -39.402B | 13.252B | 33.211B | 35.207B | 20.734B | 23.593B | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 2.527K | 2.109K | 2.222K | 1.694K | 1.702K | 2.131K | 2.013K | 3.149K | 2.368K | 1.928K | 2.16K | 1.693K | 1.685K | 1.274K |
| Price performance 12m | 0.2 | -0.05 | 0.31 | -0 | -0.2 | 0.06 | -0.36 | 0.33 | 0.23 | -0.11 | 0.28 | 0 | 0.32 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 602B | 613B | 614B | 595B | 592B | 602B | 624B | 646B | 646B | 683B |
| ↳ YoY growth | -1.7% | +1.8% | +0.2% | -3.1% | -0.5% | +1.7% | +3.5% | +3.6% | -0.1% | +5.7% |
| ↳ 5y CAGR | -0.7% | +0.0% | +0.3% | +1.0% | +1.6% | +2.9% | ||||
| Other receivables (JPY) | 52.8B | 76.5B | 80.3B | 77.8B | 80.1B | 76.7B | 82.1B | 87.2B | 84.4B | 93.5B |
| Borrowings, current (JPY) | 549M | 859M | 760M | 570M | 240M | 48M | — | — | — | — |
| Borrowings, non-current (JPY) | 1.29B | 1.21B | 951M | 630M | 389M | — | — | 30B | 30B | 30B |
| Bonds payable (JPY) | — | — | — | — | — | — | — | 20B | 20B | 20B |
| Lease liabilities (JPY) | 4.72B | 4.58B | 5.04B | 5.97B | 5.54B | 4.99B | 3.86B | 4.94B | 5.55B | 5.62B |
| Cash and deposits (JPY) | 164B | 192B | 206B | 211B | 170B | 180B | 160B | 214B | 177B | 193B |
| Intangible assets (JPY) | 13.8B | 12.1B | 17.4B | 17.6B | 17.4B | 18.8B | 17.9B | 16.6B | 11.5B | 13.1B |
| Net debt (borrowings + leases - cash) (JPY) | -158B | -185B | -200B | -203B | -164B | -175B | — | -179B | -142B | -157B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 34.3B | 47.6B | 46.9B | 33.8B | -21.2B | 36.5B | 13.1B | 86.4B | 5.64B | 38.6B |
| Purchases of property, plant and equipment (JPY) | -10.6B | -9.8B | -11.2B | -19B | -15.1B | -15B | -22.7B | -12.7B | -16.5B | -22.5B |
| Purchases of intangible assets (JPY) | -2.96B | -2.57B | -2.47B | -1.58B | -3.16B | -1.99B | -2.75B | -2.59B | -3.62B | -6.07B |
| Change in receivables (cash effect) (JPY) | 12.8B | -36.1B | -3.02B | 19.9B | 4.19B | -7.47B | -26.4B | -25.2B | 2.52B | -44.2B |
| Change in inventories (cash effect) (JPY) | 2.79B | -1.44B | 1.46B | -15.2B | 933M | 1.65B | -5.9B | -3.58B | -11.2B | -5.18B |
| Change in payables (cash effect) (JPY) | -11B | 29.4B | 1.15B | -18.7B | -45B | 951M | 25.1B | 75B | -24.3B | 47.1B |
| Dividends paid (cash effect) (JPY) | -7.37B | -8.23B | -9.41B | -10.4B | -10.8B | -11.4B | -11.1B | -12.2B | -12.6B | -12B |
| Share buybacks (cash effect) (JPY) | -3M | -4M | -13.3B | -2M | -2M | -15.3B | -2M | -35.7B | -11B | -638M |
| Interest paid (cash effect) (JPY) | -103M | -93M | -92M | -98M | -85M | -73M | -64M | -132M | -278M | -355M |
| Income taxes paid (cash effect) (JPY) | -21.2B | -10.4B | -17.6B | -21.8B | -18.1B | -9.02B | -18.1B | -12.3B | -14.3B | -13B |
| Operating cash flow before change in receivables (JPY) | 21.5B | 83.7B | 49.9B | 13.9B | -25.4B | 44B | 39.5B | 112B | 3.12B | 82.7B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 20.7B | 35.2B | 33.2B | 13.3B | -39.4B | 19.6B | -12.4B | 71.1B | -14.5B | 10B |
| Income detail | ||||||||||
| Research and development expense (JPY) | 1.14B | 1.16B | 1.25B | 1.4B | 1.44B | 1.37B | 2.09B | 2.2B | 1.9B | 2.33B |
| ↳ 5y CAGR | +5.1% | +3.8% | +12.6% | +12.0% | +6.3% | +10.1% | ||||
| Total comprehensive income (JPY) | 34.6B | 50.2B | 29.8B | 43.5B | 27.1B | 8.46B | 27.6B | 39B | 25.4B | 39.3B |
| Comprehensive income to owners (JPY) | 34.3B | 50.1B | 29.8B | 43.4B | 27.1B | 8.44B | 27.6B | 39B | 25.3B | 39.2B |
| Provision for credit losses (JPY) | — | — | 205M | 1.5B | -608M | 1.25B | -386M | -1.16B | 192M | 338M |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | 0.0% | 0.2% | 0.1% | 0.2% | 0.1% | 0.2% | 0.0% | 0.0% |
| Segments | ||||||||||
| Dispensing Pharmacy And Related Businesses · Segment revenue (JPY) | — | — | — | — | — | — | — | — | 37B | 37.2B |
| ↳ YoY growth | +0.4% | |||||||||
| Dispensing Pharmacy And Related Businesses · Segment operating income (JPY) | — | — | — | — | — | — | — | — | 596M | 499M |
| Reported | Jun 27, 2017 | Jun 26, 2018 | Jun 25, 2020 | Jun 25, 2020 | Jun 25, 2021 | Jun 28, 2022 | Jun 27, 2023 | Jun 26, 2024 | Jun 23, 2026 | Jun 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Alfresa Holdings Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVDV | 0.21% | 2,797,400 | $ 41.127M | Nov 16, 2026 |
| DISV | 0.17% | 591,501 | $ 8.49M | Nov 12, 2026 |
| AVDS | 0.10% | 24,400 | $ 358.724K | Nov 16, 2026 |
| DFIS | 0.06% | 249,401 | $ 3.58M | Nov 12, 2026 |
| AVSD | 0.05% | 11,500 | $ 169.071K | Nov 16, 2026 |
| AVDE | 0.03% | 422,700 | $ 6.214M | Nov 16, 2026 |
| DXIV | 0.03% | 4,900 | $ 70.328K | Nov 12, 2026 |
| DFSI | 0.02% | 18,300 | $ 262.655K | Nov 12, 2026 |
| DFIC | 0.02% | 206,000 | $ 2.957M | Nov 12, 2026 |
| DFAX | 0.01% | 117,500 | $ 1.686M | Nov 12, 2026 |
| DFIV | 0.01% | 164,701 | $ 2.364M | Nov 12, 2026 |
| DFAI | 0.01% | 118,100 | $ 1.695M | Nov 12, 2026 |